glp 1 stories We’ve heard the GLP-1 success and also some horror stories., But here are three things you might not have heard., #glpmeds #glp-1 #weightlossinprogress Women's Haven® | Period Care

In a 1-year trial, patients who were administered lorcaserin lost an average of 5% of their body weight, while those in the placebo group only lost an average of 2% Medication update: The FDA has withdrawn lorcaserin, a medication used to treat obesity, due to concerns about its potential side effects

The Lixisenatide study was a carefully conducted and well constructed investigation

Many longevity experts recommend you set your daily protein intake at 1.2 to 1.6 grams per kilogram of bodyweight

AMPK, together with mTOR and its downstream target S6K1, integrate nutrient and hormonal signals to maintain energy homeostasis AMPK is a nutrient and energy sensor

Retatrutide is a novel triple hormone receptor agonist with promising results in phase II clinical trials for obesity and T2DM treatment (Table 3)

Cardiovascular Effects GLP-1 analogs are gaining interest for their cardiovascular effects beyond glucose or body weight control, as both central and peripheral activation of GLP-1 receptors has a range of impacts on heart rate (HR) and blood pressure (28, 128)